<DOC>
	<DOCNO>NCT01617824</DOCNO>
	<brief_summary>Diabetes mellitus characterize chronic low grade inflammation , worsen co-existence renal failure . One key aspect chronic inflammatory disease alteration polarization profile circulate monocyte-macrophage cell . Namely , monocytes-macrophages exist pro-inflammatory ( M1 ) polarize form anti-inflammatory ( M2 ) polarize state . Alterations M1/M2 balance think contribute inflammation within atherosclerotic lesion visceral adipose tissue , turn , worsen cardiovascular disease metabolic feature type 2 diabetic patient . M1 M2 regulate complex interplay soluble signal molecule , many substrate enzyme DPP-4 ( dipeptidyl peptidase-4 ) . Therefore , inhibition DPP-4 affect M1/M2 polarization balance . In clinical trial , investigator test whether DPP-4 inhibitor Linagliptin , compare placebo , modifies M1/M2 balance type 2 diabetic patient without chronic renal failure . In addition , test whether DPP-4 inhibition Linagliptin acutely affect endothelial progenitor cell ( EPCs ) , vasculoprotective cell implicate pathobiology diabetic complication .</brief_summary>
	<brief_title>Rapid Effects Linagliptin Monocyte Polarization Endothelial Progenitor Cells Type 2 Diabetes</brief_title>
	<detailed_description>Type 2 diabetes associate chronic sterile low-grade inflammation , usually cause hyperglycemia associate biochemical abnormality , well overweight/obesity . The co-existence chronic renal failure exacerbate inflammation diabetic patient , contribute exceedingly high morbidity mortality category patient . One key element type inflammation pro- versus anti-inflammatory polarization circulate monocyte tissue macrophage . Diabetes indeed cause imbalance polarization , favour pro-inflammatory ( M1 ) monocytes expense anti-inflammatory ( M2 ) monocytes . Cells belonging monocyte/macrophage lineage great importance diabetes pathophysiology , involve atherosclerosis adipose tissue biology , determine diabetes outcomes . It recognize M1/M2 polarization relies expression chemokines/cytokines respective receptor . Interestingly , among non-incretin substrate DPP-4 several chemokines ( e.g . MCP-1 -2 , RANTES SDF-1a ) , may regulate M1/M2 polarization . Linagliptin ( terminal half-life &gt; 100 hour , effective half-life accumulation approximately 12 hour ) safely use type 2 diabetic patient renal impairment without dose adjusting , drug excrete &gt; 90 % feces minor renal excretion . The possibility modulate M1/M2 inflammatory pathway DPP-4 inhibitor linagliptin entail hitherto unappreciated opportunity protect diabetic patient renal disease detrimental consequence chronic inflammation vascular adipose tissue biology . We set protocol ass M1/M2 polarization circulate monocyte/macrophage cell flow cytometry . Our preliminary data indicate diabetes associate imbalance M1/M2 polarization versus non diabetic control , favour M1 cell diabetic patient . Hyperglycemia per se may affect M1/M2 polarization expect effect linagliptin monocyte detect soon DPP-4 inhibition reach steady-state . Therefore , order provide proof-of-concept effect linagliptin M1/M2 polarization avoid confound improve glucose control , time point study short ( 4 day ) . Our preliminary data cell culture indicate day treatment stimulus sufficient modulate monocyte/macrophage polarization . This provide valuable information direct effect drug inflammatory pathway . Endothelial progenitor cell ( EPCs ) vasculoprotective cell release bone marrow ( BM ) response ischemia , hypoxia tissue injury . Once bloodstream , EPCs home damage tissue help restore healthy functional vasculature , mean endothelial repair angiogenesis . In steady-state condition , CD34+KDR+ EPCs circulate peripheral blood ( PB ) low level release BM coordinate sympathetic nervous system . It demonstrate level EPC generic CD34+ PC predictor future cardiovascular event , cardiovascular death all-cause mortality . We previously show Sitagliptin raise EPCs level 4 week . Herein , aim confirm finding use Linagliptin , short time point .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Type 2 diabetes eGFR &gt; 60 mL/min/1.73 mq ( patient without renal failure ) eGFR 1060 mL/min/1.73 mq ( patient renal failure ) Type 1 diabetes Hypersensitivity Linagliptin excipients Intolerance DPP4 inhibitor Terminal renal failure ( eGFR &lt; 10 mL/min/1.73 mq ) Use GLP1 analog DPP4 inhibitor Recent ( within 1 month ) trauma surgery acute diseases Any acute chronic inflammatory condition Immunosuppression organ transplantation Pregnancy lactation Inability provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Kidney</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Metabolism</keyword>
</DOC>